NASDAQ:NCNA NuCana (NCNA) Stock Price, News & Analysis $2.80 +0.05 (+1.82%) (As of 07/5/2024 08:53 PM ET) Add Compare Share Share Today's Range$2.70▼$2.9350-Day Range$2.55▼$4.0152-Week Range$2.53▼$21.52Volume16,000 shsAverage Volume44,599 shsMarket Capitalization$7.39 millionP/E RatioN/ADividend YieldN/APrice Target$125.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrends Get NuCana alerts: Email Address NuCana MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside4,364.3% Upside$125.00 Price TargetShort InterestHealthy1.71% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($11.11) to ($11.60) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.64 out of 5 stars 3.5 Analyst's Opinion Consensus RatingNuCana has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageNuCana has received no research coverage in the past 90 days.Read more about NuCana's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.71% of the float of NuCana has been sold short.Short Interest Ratio / Days to CoverNuCana has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NuCana has recently decreased by 10.43%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldNuCana does not currently pay a dividend.Dividend GrowthNuCana does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NCNA. Previous Next 0.6 News and Social Media Coverage Search Interest1 people have searched for NCNA on MarketBeat in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NuCana insiders have not sold or bought any company stock.Percentage Held by Insiders31.20% of the stock of NuCana is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions44.00% of the stock of NuCana is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about NuCana's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for NuCana are expected to decrease in the coming year, from ($11.11) to ($11.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NuCana is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NuCana is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNuCana has a P/B Ratio of 0.32. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about NuCana's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 Media[Urgent] Hedge Funds Expect Major Crypto MovesIn the year following Bitcoin’s last Halving event, that happened in May of 2020… Bitcoin shot up over 550%. But that’s not all… Click here to register now. About NuCana Stock (NASDAQ:NCNA)NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.Read More NCNA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NCNA Stock News HeadlinesJune 30, 2024 | americanbankingnews.comNuCana (NASDAQ:NCNA) Trading Down 6.9%May 30, 2024 | globenewswire.comNuCana to Present at the Jefferies Global Healthcare ConferenceJuly 8, 2024 | The Freeport Society (Ad)Operation Replace Biden is a GoLast night’s debate proved me right: Joe Biden will be replaced. I’ve been making this warning for months… and people laughed at me.May 21, 2024 | finance.yahoo.comNuCana to Present at TD Cowen’s 5th Annual Oncology Innovation SummitMay 21, 2024 | globenewswire.comNuCana to Present at TD Cowen's 5th Annual Oncology Innovation SummitMay 16, 2024 | msn.comNCNA Stock Earnings: NuCana Beats EPS for Q1 2024May 16, 2024 | finanznachrichten.deNuCana plc: NuCana Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 16, 2024 | globenewswire.comNuCana Reports First Quarter 2024 Financial Results and Provides Business UpdateJuly 8, 2024 | The Freeport Society (Ad)Operation Replace Biden is a GoLast night’s debate proved me right: Joe Biden will be replaced. I’ve been making this warning for months… and people laughed at me.May 1, 2024 | globenewswire.comNuCana Regains Compliance with Nasdaq Minimum Bid Price RequirementApril 18, 2024 | finance.yahoo.comNuCana plc (NCNA)April 16, 2024 | finance.yahoo.comNuCana Announces Completion of ADS Ratio ChangeApril 9, 2024 | globenewswire.comNuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical StudyApril 5, 2024 | benzinga.comNuCana Stock (NASDAQ:NCNA), Quotes and News SummaryMarch 28, 2024 | msn.comWhy NuCana (NCNA) Shares Are Trading LowerMarch 27, 2024 | finanznachrichten.deNuCana plc: NuCana Announces Plan to Implement ADS Ratio ChangeMarch 27, 2024 | marketwatch.comNuCana American Depositary Shares Fall on News of Planned Ratio ChangeMarch 27, 2024 | globenewswire.comNuCana Announces Plan to Implement ADS Ratio ChangeSee More Headlines Receive NCNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NuCana and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/16/2024Today7/08/2024Next Earnings (Estimated)8/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:NCNA CUSIPN/A CIK1709626 Webwww.nucana.com Phone441313571111FaxN/AEmployees25Year FoundedN/APrice Target and Rating Average Stock Price Target$125.00 High Stock Price Target$150.00 Low Stock Price Target$100.00 Potential Upside/Downside+4,364.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($11.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-34,370,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-143.48% Return on Assets-83.22% Debt Debt-to-Equity RatioN/A Current Ratio1.53 Quick Ratio1.53 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.85 per share Price / Book0.32Miscellaneous Outstanding Shares2,640,000Free Float1,818,000Market Cap$7.39 million OptionableNot Optionable Beta0.99 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Hugh Stephen Griffith (Age 56)Founder, CEO & Executive Director Comp: $1.24MMr. Donald Munoz (Age 55)Chief Financial Officer Mr. David Harrison (Age 64)Head of Translational Medicine Dr. Jeffrey D. Bloss F.A.C.O.G. (Age 66)M.D., Chief Medical Officer Ms. Theresa BruceSenior Vice President of Clinical OperationsMs. Elisabeth OelmannSenior Vice President of Medical & Clinical DevelopmentMartin QuinnCompany SecretaryMore ExecutivesKey CompetitorsImmunoPrecise AntibodiesNASDAQ:IPAEnlivex TherapeuticsNASDAQ:ENLVRenovoRxNASDAQ:RNXTAcasti PharmaNASDAQ:ACSTVYNE TherapeuticsNASDAQ:VYNEView All Competitors NCNA Stock Analysis - Frequently Asked Questions How have NCNA shares performed this year? NuCana's stock was trading at $7.3950 on January 1st, 2024. Since then, NCNA stock has decreased by 62.1% and is now trading at $2.80. View the best growth stocks for 2024 here. How were NuCana's earnings last quarter? NuCana plc (NASDAQ:NCNA) announced its quarterly earnings data on Thursday, May, 16th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($3.31) by $3.15. When did NuCana's stock split? NuCana shares reverse split on Tuesday, April 16th 2024. The 1-25 reverse split was announced on Tuesday, April 16th 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 16th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. When did NuCana IPO? NuCana (NCNA) raised $100 million in an initial public offering on Thursday, September 28th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. Citigroup, Jefferies and Cowen served as the underwriters for the IPO and William Blair was co-manager. How do I buy shares of NuCana? Shares of NCNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of NuCana own? Based on aggregate information from My MarketBeat watchlists, some other companies that NuCana investors own include Wirecard (WDI), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Ovid Therapeutics (OVID), SCYNEXIS (SCYX), Aldeyra Therapeutics (ALDX) and Allena Pharmaceuticals (ALNA). This page (NASDAQ:NCNA) was last updated on 7/8/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredWhy is NVDA stumbling?July is historically the best month of the year for U.S. stocks. So why are everyone’s favorite tech stocks...Chaikin Analytics | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredObama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happ...Porter & Company | SponsoredTrump’s Gift Could Unleash $51 Billion in New WealthIn January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house...Wealthpin Pro | SponsoredNew Government Policy to Wipe Out Seniors WealthDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NuCana plc Please log in to your account or sign up in order to add this asset to your watchlist. Share NuCana With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.